In contrast, the opposition or antagonism of PD-1 has demonstrated a significant boost in anti-tumor immunity, indicating that blocking PD-1 can potentially unleash an effective attack on cancer cells by enhancing the T cell response against them [11,12]. Here, PDCD1 is linked to neoplasm.